Advertisement

Development of Antibody-Based Therapeutics

Translational Considerations & Challenges

  • Mohammad A. Tabrizi
  • Gadi G. Bornstein
  • Scott L. Klakamp

Table of contents

  1. Front Matter
    Pages i-viii
  2. Mohammad A. Tabrizi
    Pages 1-4
  3. Vaishnavi Ganti, Mohammad A. Tabrizi
    Pages 5-18
  4. Mohammad A. Tabrizi, Scott L. Klakamp
    Pages 19-40
  5. Gopalan Raghunathan, Edward Hsieh, Grigori Ermakov
    Pages 41-69
  6. Andrew W. Drake, Yasmina N. Abdiche, Giuseppe A. Papalia
    Pages 71-132
  7. Laurence Fayadat-Dilman
    Pages 133-160
  8. Mohammad A. Tabrizi, Shraddha S. Sadekar, Isabel Figueroa, Ayse M. Ovacik
    Pages 161-170
  9. Shraddha Sadekar, Isabel Figueroa, Harish Shankaran
    Pages 171-186
  10. Glareh Azadi, Gulesi Ayanoglu, Vaishnavi Ganti, Harish Shankaran, Mohammad A. Tabrizi
    Pages 187-196
  11. Mohammad A. Tabrizi, Isabel Figueroa, Wendy Blumenschein, Jeff Grein
    Pages 197-206
  12. Xiaochen Zhao, Xiaoning Wang, Yan Feng, Shruti Agrawal, Dhaval K. Shah
    Pages 207-222
  13. Mohammad A. Tabrizi, Scott L. Klakamp
    Pages E1-E2

About this book

Introduction

With a key focus on recent developments and advances in the field, this book provides in-depth coverage of topics fundamental to the development of targeted therapeutics. The expansion of targeted modalities in rapidly evolving therapeutic areas, such as immune-oncology, and developments with respect to combination therapies, novel technologies, and the therapeutic application of antibody-drug conjugates, are presented. Additionally, the book builds upon topics discussed in the first edition (2012) where recent innovations warrant elaboration. 
This, the second edition of Development of Antibody-Based Therapeutics: Translational Considerations, represents a comprehensive evaluation of progress in the field, which sits alongside the first edition to inform, in detail, professional and academic researchers, as well as graduate students.
Mohammad A. Tabrizi, Ph.D. is a leader in translational sciences as related to development of antibody-based therapeutics. His product development experience spans many therapeutic areas including oncology and inflammatory disease, and his technical expertise includes preclinical pharmacology and safety, preclinical and clinical pharmacokinetics, pharmacodynamics, GLP-compliant bioanalytics, and clinical pharmacology of therapeutic monoclonal antibodies.

Gadi Bornstein, Ph.D. has over seventeen years of experience in Oncology R&D with an emphasis in preclinical antibody discovery and development. Dr. Bornstein currently leads and directs biologics discovery efforts at TESARO. He received his B.S. in biochemistry at the University of California, Davis and his doctoral degree in biochemistry at the University of Southern California Keck School of Medicine. Dr. Bornstein completed his postdoctoral training at Stanford University in the Division of Immunology and Rheumatology. 

Following his postdoctoral training, Dr. Bornstein joined Amgen Fremont, Inc. (formerly Abgenix, Inc.) as a Staff Scientist in the Preclinical Oncology department. Dr. Bornstein has held roles of increasing responsibility at AstraZeneca, Pfizer, and Novartis, where he was a project team leader, lead biologist, and key contributor to scientific strategies for multiple oncology programs. Dr. Bornstein has authored numerous research papers, reviews, as well as book chapters, and is a co-inventor on multiple patents.

Scott L. Klakamp, Ph.D. is one of the leading scientists in utilizing Surface Plasmon Resonance (SPR) and KinExA® to measure the binding kinetics and equilibrium dissociation constants of human monoclonal antibody/antigen complexes. He was the founder of SKD Consulting LLC and acted as Principal Consultant at that company during the development of this title. Prior to SKD Consulting LLC, he was the Vice President of Chemistry and Biochemistry at BiOptix Inc., a company that provided the 404pi biosensor. Dr. Klakamp has also held positions of increasing responsibility in the areas of analytical and biophysical characterization at Chiron, Amgen/Abgenix, AstraZeneca/MedImmune, and Takeda Pharmaceuticals.

Dr. Klakamp has been an author on over 30 research and review papers, book chapters, and patents. He has also been an invited speaker at numerous international and national meetings.  Dr. Klakamp received his B.A. in Chemistry from Houghton College and his PhD in Chemistry at the Pennsylvania State University. From 1990 to 1993, he completed a postdoctoral fellowship (funded by a National Research Service Award from the National Institutes of Health) at the California Institute of Technology in bioinorganic chemistry.

Keywords

Monospecific concepts Bi-specific constructs Nanobodies Immune-oncology Cancer Preclinical studies Combination therapies Immune system Biophysical characterization Biomarkers Pharmacokinetics Pharmacodynamics Cross-reactivity Relevant species First-in-human dosing Dosing strategy Design criteria

Editors and affiliations

  • Mohammad A. Tabrizi
    • 1
  • Gadi G. Bornstein
    • 2
  • Scott L. Klakamp
    • 3
  1. 1.Merck & Co., Inc.Palo AltoUSA
  2. 2.Biologics DiscoveryTESAROWalthamUSA
  3. 3.SKD Consulting LLCBroomfieldUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-981-13-0496-5
  • Copyright Information Springer Nature Singapore Pte Ltd. 2018
  • Publisher Name Adis, Singapore
  • eBook Packages Medicine
  • Print ISBN 978-981-13-0495-8
  • Online ISBN 978-981-13-0496-5
  • Buy this book on publisher's site